Issue of Shares

Amirose London Holdings

11/06/2025 07:00

RNS Number : 2944M

Amirose London Holdings PLC

11 June 2025

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

 

11 June 2025 

 

 

Amirose London Holdings PLC

 

(the "Company" or "Amirose")

 

Issue of Shares

 

Amirose London Holdings PLC is pleased to announce that it has raised gross proceeds of £100,000 from an investor through the subscription of 2,000,000 new ordinary shares ("Subscription Shares") at the price of £0.005 per share ("Subscription Price") under existing unspent share authorities.  

 

Novum has been issued 288,000 Ordinary Shares at £0.005 for services under its retainer with Amirose ("Novum Shares").

 

Application has been made for the Subscription Shares and the Novum Shares to be admitted to trading on the Aquis Stock Exchange Growth Market on or around 16 June 2025 ("Admission") and the Subscription Shares and Novum Shares will rank pari passu with the ordinary shares of the Company in issue. 

 

On Admission the Company will have 121,071,865 ordinary shares in issue, each ordinary share with one voting right. This number should be used by shareholders as the denominator for the calculation by which shareholders will determine if they are required to notify their interest in, or a change to their interest in the Company.  

 

Michael Heath, Chief Executive Officer and Finance Director of Amirose, commented: '"We are delighted to announce the successful completion of this further subscription, which demonstrates strong investor confidence in Amirose and our long-term strategy. The additional capital will enable us to accelerate our growth initiatives and deliver further value to our shareholders."

 

For further information, please contact:

Amirose London Holdings PLC
Michael Heath
Chief Executive Officer
+44 7391 407 210
Alfred Henry Corporate Finance (Corporate Advisor)
Nick Michaels/Maya Klein Wassink
+44 (0) 20 8064 4056
Capital Plus Partners Limited(Broker)
Dominic Berger
+44 (0) 7799 888 544
Novum Securities Limited(Broker)
Jon Belliss/Colin Rowbury
+44 20 7399 9400

 

 

About Amirose London Holdings PLC  

Amirose provides contract manufacturing services in the personal care sector for global and boutique premium brands. Amirose will assist such brands in developing formulations for personal care products, sourcing packaging, bulk manufacturing, filling and distributing. Amirose also helps customers navigate the regulatory and compliance framework required to bring a product to market. Amirose has approximately 75 customers and services over 200 brands. Amirose's manufacturing facilities are in Thetford, Norfolk. Amirose currently has 86 employees.

Amirose aims to transform its contract manufacturing business, which has so far generated modest profits while utilising only a portion of its factory's capacity, into a thriving enterprise by fully leveraging excess capacity, infrastructure, and the expertise of its team. Amirose expects to drive growth organically and through strategic acquisitions in the future.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NEXFBLLFEQLLBBB